Key result
Recent advances in perioperative management, including pharmacological agents and extracorporeal life support, aim to optimize myocardial and cerebral protection in pediatric cardiac surgery.
Why the study?
What are the recent developments in perioperative management strategies to prevent and treat complications in pediatric patients undergoing open heart surgery for congenital heart disease?
What are the recent developments in perioperative management strategies to prevent and treat complications in pediatric patients undergoing open heart surgery for congenital heart disease?
This review summarizes recent advances in perioperative management to optimize outcomes and minimize complications in pediatric patients undergoing congenital heart surgery.
May guide perioperative decisions in pediatric cardiac surgery; leaves open the need for prospective validation of these strategies.
PURPOSE OF REVIEW: Survival of infants born with complex cardiac anomalies has dramatically improved, and the growing population of patients with congenital heart disease reaching adulthood has resulted in an increased incidence of long-term complications related to the perioperative period. This review focuses on recent advances in strategies to prevent, detect, treat, or predict early and late complications arising from open heart surgery for congenital heart disease. RECENT FINDINGS: Aprotinine and recombinant factor VIIa may effectively reduce the risk of excessive perioperative bleeding, and the use of steroids, complement component C4A, heparin-coated circuits, and modified ultrafiltration may play a role in the control of the postoperative inflammatory response. Milrinone is becoming increasingly popular in the prevention and treatment of the reduced postoperative cardiac output, and extracorporeal life support has become a well established and successful form of support for postoperative myocardial dysfunction, even in the functionally univentricular heart. In recent years interest increased in optimizing myocardial protection using contents-differentiated and temperature-differentiated blood cardioplegia and in optimizing cerebral protection using a higher haematocrit during bypass and by using selective regional perfusion in favour of circulatory arrest. SUMMARY: Hearts can be mended, but salvation of hearts and brains needs further rigorous attention.
No takes yet. Share an insight, caveat, or question.
Stöcker et al. (2006) conducted a review in Congenital heart disease. Perioperative management strategies was evaluated. Recent advances in perioperative management, including pharmacological agents and extracorporeal life support, aim to optimize myocardial and cerebral protection in pediatric cardiac surgery.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: